Skip to main content

Nexentis Technologies Inc.

corporate_fare Company Profile

Nexentis Technologies Inc.

NXTS·NASDAQ·Life Sciences·CIK 0001789192

Nexentis Technologies Inc., through its subsidiary, develops therapeutics for cancer and inflammatory metabolic diseases. The company operates through two segments: Biotechnology Activity and Renewable Energy Projects. Its product pipeline includes MITOLINE, an algorithm designed for multiple sequence/structure pairwise alignments to generate 3D comparative models of mitochondrial carrier proteins. The company also offers a cloud-based computational chemistry platform, novel in-vitro screening platforms, and advanced 3D NSCLC tumor spheroid systems. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel. The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026.

Nexentis Technologies Inc. (NASDAQ:NXTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for NXTS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Nexentis Subsidiary MitoCareX Bio Optimizes Hit Molecule, Reaching Key Drug Discovery Milestone
  • Nexentis Technologies Files $100M Universal Shelf Registration Amidst Going Concern Warning and Recent Reverse Stock Split
  • Nexentis Technologies to Implement 1-for-7 Reverse Stock Split to Maintain Nasdaq Listing
  • Nexentis Technologies Reports $4.16M Net Loss, $(3.54) EPS in 2025 10-K
  • Nexentis Technologies Reports Substantial Going Concern Doubt, $4.16M Net Loss, and High Dilution Amid Strategic Pivot

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$4M
Diluted EPS
-$8.61
Op. Cash Flow
-$3.81M
Free Cash Flow
-$3.82M
Operating Income
-$4.23M
Cash & Equivalents
$3.83M
Total Debt
$1.21M
Debt / Equity
0.08×
Shares Outstanding
2.77M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014183
$0.5668 -3.16% today
52-week range · as of 2026-10-20 $0.5668 – $30.28
Market cap
$1.73M
Volume
169.5K (0.2× avg)
3-mo avg 801K
Live data · 2026-11-02 04:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NXTS - Filings & News (Page 2)

NXTS
May 13, 2026, 7:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Nexentis Subsidiary MitoCareX Bio Optimizes Hit Molecule, Reaching Key Drug Discovery Milestone
Price at Filing: $4.57
Real-time Price: $0.5668 info
Change: -$4.01 (-88%) info
Market Cap: $1.734M info
Sentiment: Positive
View Wiseek Article
NXTS
Apr 16, 2026, 4:15 PM EDT
Filing Type: S-3
Importance Score:
8
Nexentis Technologies Files $100M Universal Shelf Registration Amidst Going Concern Warning and Recent Reverse Stock Split
Price at Filing: $3.97
Real-time Price: $0.5668 info
Change: -$3.40 (-86%) info
Market Cap: $1.734M info
Sentiment: Negative
View Wiseek Article
NXTS
Apr 06, 2026, 8:39 AM EDT
Filing Type: 8-K
Importance Score:
8
Nexentis Technologies to Implement 1-for-7 Reverse Stock Split to Maintain Nasdaq Listing
Price at Filing: $0.670
Real-time Price: $0.5668 info
Change: Reverse Stock Split info
Market Cap: $1.734M info
Sentiment: Negative
View Wiseek Article
NXTS
Mar 31, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
8
Nexentis Technologies Reports $4.16M Net Loss, $(3.54) EPS in 2025 10-K
Price at Filing: $0.660
Real-time Price: $0.5668 info
Change: Reverse Stock Split info
Market Cap: $1.734M info
Sentiment: Negative
View Wiseek Article
NXTS
Mar 31, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
9
Nexentis Technologies Reports Substantial Going Concern Doubt, $4.16M Net Loss, and High Dilution Amid Strategic Pivot
Price at Filing: $0.660
Real-time Price: $0.5668 info
Change: Reverse Stock Split info
Market Cap: $1.734M info
Sentiment: Negative
View Wiseek Article
NXTS
Mar 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Nexentis Completes Divestiture of Save Foods Subsidiary, Acquires 19.99% Stake in Voice Assist
Price at Filing: $0.761
Real-time Price: $0.5668 info
Change: Reverse Stock Split info
Market Cap: $1.734M info
Sentiment: Neutral
View Wiseek Article
NXTS
Mar 12, 2026, 11:26 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Massive Dilution, Reverse Split, and Unfavorable Financing Terms
Price at Filing: $0.9311
Real-time Price: $0.5668 info
Change: Reverse Stock Split info
Market Cap: $1.734M info
Sentiment: Negative
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets